Albuterol Sulfate — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.05 mg/kg	q8h	Duration: As needed for symptom control Notes: Use with caution in dogs with cardiac disease. May cause tachycardia.
Dog	Inhalation (via metered-dose inhaler with spacer)	90-180 mcg (1-2 puffs)	q12h or as needed	Duration: As needed Notes: Use a canine aerosol mask and spacer. Monitor for adverse effects.
Cat	PO	0.05 mg/kg	q8h	Duration: As needed Notes: May cause agitation or tachycardia. Use with caution in hyperthyroid cats.
Cat	Inhalation (via metered-dose inhaler with spacer)	90-180 mcg (1-2 puffs)	q12h or as needed	Duration: As needed Notes: Use a feline aerosol mask and spacer. Administer after bronchodilator if using corticosteroids.
Horse	PO	0.8-1.0 mcg/kg	q12h	Duration: Chronic therapy for heaves Notes: May cause sweating, muscle tremors, and tachycardia. Monitor serum potassium.
Horse	Inhalation (nebulized)	360-720 mcg (4-8 puffs of 90 mcg)	q6-8h	Duration: Acute exacerbations Notes: Use a nebulizer with a mask. Onset within 5 minutes.
Cattle	IM or SC	0.02 mg/kg	q12h	Duration: 3-5 days Notes: Extra-label use; not FDA-approved for cattle. Observe withdrawal times.
Small Ruminants (sheep/goats)	PO	0.05 mg/kg	q8h	Duration: As needed Notes: Extra-label use; monitor for hyperglycemia.
Rabbit	Inhalation (nebulized)	2.5 mg (0.5 mL of 0.5% solution)	q12h	Duration: As needed Notes: Use a pediatric nebulizer mask. May cause tachycardia.
Bird/Poultry	Inhalation (nebulized)	0.5-1.0 mg/kg	q12h	Duration: As needed Notes: Extra-label; use with caution in small birds due to potential toxicity.

Clinical Indications & Species Uses

General Indications

Bronchodilation in acute and chronic respiratory conditions characterized by reversible airway obstruction

Dog (Canine)

Bronchospasm associated with asthma
Chronic bronchitis
Tracheal collapse
Allergic airway disease

Cat (Feline)

Feline bronchial asthma
Chronic bronchitis
Allergic airway disease

Horse (Equine)

Recurrent airway obstruction (heaves)
Inflammatory airway disease
Exercise-induced bronchospasm
Chronic obstructive pulmonary disease (COPD)

Cattle (Bovine)

Bovine respiratory disease complex (adjunctive therapy)
Enzootic pneumonia (adjunctive)
Bronchospasm due to respiratory infections

Small Ruminants (Sheep / Goat)

Respiratory disease with bronchospasm (e.g., pneumonia, parasitic bronchitis)

Rabbit & Small Mammals

Bronchospasm secondary to respiratory infections
Asthma-like conditions (rarely used)

Exotic & Other Species

Guinea pigs: bronchospasm; Rats/mice: research use; Ferrets: asthma-like conditions (off-label)

Pharmacology & Mechanism of Action

Drug Class: Bronchodilator | Pharmacological Group: Beta-2 Adrenergic Agonist

Mechanism of Action: Albuterol sulfate is a selective beta-2 adrenergic receptor agonist that stimulates adenylate cyclase, leading to increased intracellular cyclic AMP (cAMP) in bronchial smooth muscle. Elevated cAMP activates protein kinase A, which phosphorylates target proteins, resulting in relaxation of bronchial smooth muscle, inhibition of mast cell mediator release (e.g., histamine, leukotrienes), and increased mucociliary clearance. It also causes bronchodilation by directly relaxing airway smooth muscle from the trachea to the terminal bronchioles.

Pharmacodynamics: Albuterol produces dose-dependent bronchodilation with a rapid onset (within minutes after inhalation) and a duration of action of 4-6 hours. It also has some uterine relaxant and vasodilatory effects. In horses, it can cause tachycardia and transient hypokalemia. In cattle, it may cause hyperglycemia and increased insulin secretion. Chronic use may lead to downregulation of beta-2 receptors, reducing efficacy.

⚡ Pharmacokinetics Summary

Absorption: After oral administration, albuterol is well absorbed from the gastrointestinal tract but undergoes extensive first-pass metabolism, resulting in low systemic bioavailability (about 50% in humans; similar in animals). After inhalation, a portion is absorbed from the lungs directly into the systemic circulation, providing rapid onset. In horses, oral bioavailability is approximately 30-40%.

Distribution: Albuterol is widely distributed throughout the body, with highest concentrations in the lungs, liver, and kidneys. It crosses the placenta and is excreted in milk. Volume of distribution is approximately 2 L/kg in dogs.

Metabolism: Albuterol is metabolized primarily in the liver by conjugation (sulfation) to an inactive sulfate metabolite. In horses, the major metabolite is albuterol sulfate. The metabolism is not dependent on cytochrome P450 enzymes.

Excretion: Albuterol and its metabolites are excreted primarily in the urine. In dogs, approximately 70% of an oral dose is excreted in urine within 24 hours, with about 30% as unchanged drug. Fecal excretion is minor.

Half-Life: Dog: 2-3 hours; Horse: 1.5-2 hours; Cattle: 2-3 hours; Cat: 2-4 hours (estimated)

Bioavailability: Oral: 30-50% in dogs and horses; Inhalation: 10-20% systemic bioavailability due to local deposition and first-pass metabolism.

Protein Binding: Approximately 10% bound to plasma proteins in most species.

Available Formulations & Strengths

Oral Tablet 2 mg, 4 mg (PO)

Oral Syrup 2 mg/5 mL (PO)

Metered-Dose Inhaler (MDI) 90 mcg/actuation (Inhalation)

Nebulizer Solution 0.083% (2.5 mg/3 mL), 0.5% (5 mg/mL) (Inhalation)

Injectable Solution 0.5 mg/mL (not commonly used in veterinary medicine) (IV/IM/SC)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to albuterol or any component of the formulation
Pre-existing cardiac arrhythmias (e.g., tachyarrhythmias) unless under strict veterinary supervision
Severe cardiovascular disease (e.g., hypertrophic cardiomyopathy in cats)
Concurrent use with non-selective beta-blockers (e.g., propranolol) due to antagonistic effects
Hyperthyroidism (relative contraindication due to increased risk of tachycardia)

Warnings & Clinical Precautions:

Use with caution in animals with diabetes mellitus, as albuterol may cause hyperglycemia.
Use with caution in animals with hypertension, seizure disorders, or hyperthyroidism.
In horses, monitor for hypokalemia and hyperglycemia, especially with high doses.
In cattle, extra-label use requires a valid veterinary-client-patient relationship and observance of withdrawal times.
Inhalation devices require proper mask fitting to ensure drug delivery and minimize human exposure.
Prolonged use may lead to tolerance; reassess therapy if response diminishes.
Do not use as a sole treatment for severe respiratory distress; combine with appropriate anti-inflammatory therapy (e.g., corticosteroids).

Adverse Effects & Reactions

Common:

Tachycardia
Muscle tremors
Nervousness or agitation
Hypokalemia
Hyperglycemia
Vomiting (oral administration)

Serious / Severe:

Cardiac arrhythmias (e.g., ventricular premature contractions)
Pulmonary edema (rare, especially in horses)
Paradoxical bronchospasm (inhalation)
Hypotension or hypertension
Seizures (overdose)

Rare:

Hypersensitivity reactions (urticaria, angioedema)
Metabolic acidosis
Lactic acidosis (with high doses)
Maternal and fetal tachycardia in pregnant animals

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Beta-blockers (e.g., propranolol)	Antagonizes bronchodilatory effect; may cause severe bronchospasm	High
Corticosteroids	Increased risk of hypokalemia; additive bronchodilation	Moderate
Diuretics (e.g., furosemide)	Enhanced hypokalemia	Moderate
Digoxin	Increased risk of cardiac arrhythmias due to hypokalemia	Moderate
MAO inhibitors or tricyclic antidepressants	Potentiation of cardiovascular effects	Moderate
Xanthines (e.g., theophylline)	Additive bronchodilation but increased risk of tachycardia and arrhythmias	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Severe tachycardia
Cardiac arrhythmias
Hypertension or hypotension
Muscle tremors
Hyperactivity
Hypokalemia
Hyperglycemia
Seizures
Metabolic acidosis

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Discontinue the drug. Administer a cardioselective beta-blocker (e.g., esmolol) cautiously for severe tachycardia or arrhythmias, but use with extreme caution due to risk of bronchospasm. Correct electrolyte imbalances (potassium, glucose). Provide oxygen and ventilatory support if needed. Monitor cardiac function and blood gases. In severe cases, consider activated charcoal if oral ingestion within 1-2 hours.

Food Animal Withdrawal Times

🥩 Meat: 7 days🥛 Milk: 3 days

Extra-label use in food animals requires extended withdrawal times; consult FARAD for specific recommendations. For cattle, a meat withdrawal of at least 7 days and milk withdrawal of 3 days is suggested, but these are estimates and may vary.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); protect from freezing

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep container tightly closed. Do not refrigerate MDI canisters; store with the mouthpiece down.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Albuterol sulfate is FDA-approved for human use; in veterinary medicine, it is not FDA-approved for animals but is commonly used extra-label. Some formulations (e.g., nebulizer solution) are approved for human use and may be used off-label in animals.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is permitted under AMDUCA with a valid veterinary-client-patient relationship, but requires a withdrawal time established by the veterinarian. In horses, albuterol is not approved for use in performance horses; check with racing authorities. In the EU, similar regulations apply under Regulation (EC) No 470/2009.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Albuterol is a valuable bronchodilator for managing reversible airway obstruction in small and large animals. In dogs and cats, inhalation therapy is preferred for chronic conditions to minimize systemic side effects. In horses, it is effective for heaves but should be combined with environmental management and anti-inflammatory therapy. In cattle, use is extra-label and should be reserved for cases with significant bronchospasm. Always monitor heart rate and serum potassium, especially with high doses or prolonged therapy. For acute severe bronchospasm, albuterol can be life-saving but should not replace oxygen therapy or corticosteroids. Educate owners on proper inhaler technique and mask fitting. In food animals, adhere to withdrawal times to ensure food safety.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)